Olink

Olink®
Part of Thermo Fisher Scientific

Harnessing liver–heart crosstalk via extracellular vesicle-mediated hepatic delivery of microRNAs for cardiac repair

Clinical Science, 2026

Kang J., Mun D., Yoo G., Park M., Lee J., Chung S., Yun N., Joung B.

Disease areaApplication areaSample typeProducts
CVD
Pathophysiology
Mouse Tissue Lysate
O

Olink Target 48 Mouse

Abstract

Extracellular vesicles (EVs) hold great potential to deliver microRNAs (miRNAs) in vivo; however, its preferential hepatic accumulation after systemic administration hinders the therapeutic efficacy of miRNAs. Inter-organ communication via endocrine factors is crucial for maintaining physiological homeostasis. Herein, the present study leveraged liver–heart crosstalk to overcome the hepatic tropism of EVs and reframe it as a therapeutic advantage for cardiac injury. In a mouse model of angiotensin II (Ang II)-induced cardiac injury, liver tissues showed distinct changes in inflammation-related proteins compared with saline-treated controls, indicating hepatic involvement in cardiac injury. To establish a liver–heart crosstalk-based therapeutic approach, EV@miR-155 were prepared by loading miRNA-155 into mesenchymal stem cell-derived EVs. After intravenous administration, EV@miR-155 predominantly accumulated in the liver, increased hepatic miRNA-155 levels, and remodeled the hepatic microenvironment. This remodeling suppressed PPARα-mediated production of fibroblast growth factor 21, a hepatokine implicated in cardiac pathophysiology, thereby establishing a liver–heart crosstalk axis. Remarkably, EV@miR-155 treatment significantly improved cardiac function and reduced myocardial fibrosis and hypertrophy without inducing systemic toxicity (P<0.05). Therefore, the present study provides a conceptual shift by transforming the natural hepatic tropism of EVs—traditionally regarded as a delivery limitation—into a therapeutic route that enables liver–heart crosstalk-mediated cardiac repair.

Read publication ↗